Apogee Therapeutics (APGE) Long-Term Investments (2024 - 2026)

Apogee Therapeutics (APGE) has 3 years of Long-Term Investments data on file, last reported at $198.4 million in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 18.0% year-over-year to $198.4 million in Q1 2026; TTM through Mar 2026 was $198.4 million, a 18.0% increase from a year earlier, with the FY2025 full-year figure at $172.7 million, down 17.91% from the prior year.
• Long-Term Investments for Q1 2026 stood at $198.4 million, up from $172.7 million in the prior quarter.
• Over the last five years, Long-Term Investments for APGE reached as high as $227.7 million in Q3 2024 and fell as low as $61.6 million in Q3 2025.
• Historically, Long-Term Investments has averaged $158.5 million across 3 years, with a median of $170.4 million in 2025.
• Across the five-year window, Long-Term Investments slumped 72.95% in 2025 and advanced 18.0% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $210.4 million in 2024, then declined by 17.91% to $172.7 million in 2025, then climbed by 14.83% to $198.4 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $198.4 million in Q1 2026, $172.7 million in Q4 2025, and $61.6 million in Q3 2025.